Iterum Therapeutics plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation
Amortization
Lease termination adjustments
Share-based compensation expense
Non-cash gain on short term investments
Cancellation of share options expense
Amortization of short-term investments
Interest on short-term investments
Amortization of debt discount and deferred financing costs
Interest on notes - non-cash
2025 Exchangeable Notes
Promissory Note
Financing transaction costs included in financing activities
Adjustments to fair value of derivatives
Extinguishment of debt
Other
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Income taxes
Other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of short-term investments
Proceeds from sale of short-term investments
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from PPP Loan
Repayments of long-term bank debt
Proceeds from private placement and rights offering, net of transactions costs
Proceeds from issuance of ordinary shares, net of transaction costs
Net cash provided by / (used in) financing activities

Effect of exchange rates on cash and cash equivalents
Net increase / (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, at beginning of period
Cash, cash equivalents and restricted cash, at end of period
Supplemental Disclosure of Cash Flow Information:
Income tax paid—U.S.
Interest paid
Non-cash proceeds - Pfizer Promissory Note

Comments